Current management practices for acromegaly: An international survey

Giustina, A., Bronstein, M. D., Casanueva, F. F., Chanson, P., Ghigo, E., Ho, K. K. Y., Klibanski, A., Lamberts, S., Trainer, P. and Melmed, S. (2011) Current management practices for acromegaly: An international survey. Pituitary, 14 2: 125-133. doi:10.1007/s11102-010-0269-9

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Giustina, A.
Bronstein, M. D.
Casanueva, F. F.
Chanson, P.
Ghigo, E.
Ho, K. K. Y.
Klibanski, A.
Lamberts, S.
Trainer, P.
Melmed, S.
Title Current management practices for acromegaly: An international survey
Journal name Pituitary   Check publisher's open access policy
ISSN 1386-341X
Publication date 2011-06-01
Year available 2010
Sub-type Article (original research)
DOI 10.1007/s11102-010-0269-9
Open Access Status Not yet assessed
Volume 14
Issue 2
Start page 125
End page 133
Total pages 9
Place of publication New York, NY, U.S.A.
Publisher Springer New York
Language eng
Abstract To determine whether peer-reviewed consensus statements have changed clinical practice, we surveyed acromegaly care in specialist centers across the globe, and determined the degree of adherence to published consensus guidelines on acromegaly management. Sixty-five acromegaly experts who participated in the 7th Acromegaly Consensus Workshop in March 2009 responded. Results indicated that the most common referring sources for acromegaly patients were other endocrinologists (in 26% of centers), neurosurgeons (25%) and primary care physicians (21%). In sixty-nine percent of patients, biochemical diagnoses were made by evaluating results of a combination of growth hormone (GH) nadir/basal GH and elevated insulin like growth factor-I (IGF-I) levels. In both Europe and the USA, neurosurgery was the treatment of choice for GH-secreting microadenomas and for macroadenomas with compromised visual function. The most widely used criteria for neurosurgical outcome assessment were combined measurements of IGF-I and GH levels after oral glucose tolerance test (OGTT) 3 months after surgery. Ninety-eight percent of respondents stated that primary treatment with somatostatin receptor ligands (SRLs) was indicated at least sometime during the management of acromegaly patients. In nearly all centers (96%), the use of pegvisomant monotherapy was restricted to patients who had failed to achieve biochemical control with SRL therapy. The observation that most centers followed consensus statement recommendations encourages the future utility of these workshops aimed to create uniform management standards for acromegaly.
Keyword Growth hormone
Insulin like growth factor-I
Somatostatin analogs
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status Non-UQ
Additional Notes Published online: 10 November 2010

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 61 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 66 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 18 Aug 2011, 21:25:41 EST by Matthew Lamb on behalf of School of Medicine